Research Protocol

Cagrilintide 10mg — Research Protocol

Dosage Calculator → How to Reconstitute →

Quickstart Highlights

Cagrilintide is a long‑acting acylated analogue of the pancreatic hormone amylin, designed for once‑weekly subcutaneous administration[1]. It activates central amylin receptors to promote satiety, slow gastric emptying, and reduce food intake[2][3]. In phase 2 and phase 3 trials, cagrilintide produced dose‑dependent weight loss with a predominantly gastrointestinal side‑effect profile[4][5].

    Storage Instructions

    Proper storage preserves peptide integrity and potency.

    • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
    • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days and avoid freeze–thaw cycles.
    • Allow vials to reach room temperature before opening to reduce condensation uptake.

    How It Works

    Cagrilintide is an acylated, long‑acting analogue of amylin—a hormone co‑secreted with insulin from pancreatic beta cells[2][7]. Native amylin promotes satiation, slows gastric emptying, and inhibits postprandial glucagon secretion[8][9]. By acting on central amylin receptors (particularly in the area postrema and hindbrain), cagrilintide reduces appetite and energy intake[3][10]. Lipid modifications extend its half‑life to approximately 160–195 hours, enabling once‑weekly dosing[6][11].

    Potential Benefits & Side Effects

    Observations from phase 2 and phase 3 clinical trials.

    • Weight reduction: In the phase 2 trial, cagrilintide 4.5 mg weekly produced approximately 10.8% body weight loss over 26 weeks versus 3.0% with placebo[4].
    • Combination therapy: When combined with semaglutide 2.4 mg (CagriSema), phase 3 REDEFINE trials showed approximately 20% weight loss at 68 weeks, exceeding results with either agent alone[5][12].
    • Dose‑dependent efficacy: Higher doses (2.4–4.5 mg) demonstrate greater weight loss than lower doses (0.3–1.2 mg)[4].
    • Side effects: Primarily gastrointestinal—nausea, vomiting, diarrhea, and constipation—which are generally mild‑to‑moderate and transient[4][5]. Gradual titration helps minimize these effects.

    References

    For laboratory and research use only. Minimum 98% purity. Not intended for human or animal consumption, medical, diagnostic, therapeutic or veterinary use. These statements have not been evaluated by the MHRA or FDA. This protocol is provided for educational and research purposes only and is not medical advice. The purchaser accepts full responsibility for safe handling, storage and lawful use.